No quarterly revenue total was found in FibroBiologics, Inc.'s SEC filings.
FibroBiologics, Inc. (FBLG) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$3.3 million. As of Jun 30, 2026 it held $3.5 million in cash and investments and $1.3 million in total debt.
Revenue
—
Net income
$-4.12M
+11.6% vs year-ago quarter
Operating cash flow
$-3.29M
+17.4% vs year-ago quarter
Free cash flow
$-3.29M
+21.6% vs year-ago quarter
EPS
$-0.66
+72.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.66M
-84.1% vs year-ago quarter
Net cash
$2.18M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBLG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1958777
- Former names
- FibroBiologics Inc. (until Feb 6, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.0M | -$5.1M | -$2.6M | -$5.0M | -$4.5M |
| Net income | -$4.1M | -$5.0M | -$3.2M | -$5.8M | -$4.7M |
| Diluted EPS | -$0.66 | -$1.33 | -$0.05 | -$0.13 | -$2.41 |
| Operating cash flow | -$3.3M | -$4.4M | -$3.2M | -$4.0M | -$4.0M |
| Free cash flow | -$3.3M | -$4.4M | -$3.2M | -$4.0M | -$4.2M |
| Total assets | $7.9M | $5.9M | $9.6M | $8.7M | $13.9M |
| Total liabilities | $3.3M | $3.3M | $3.5M | $8.6M | $13.0M |
| Stockholders' equity | $4.6M | $2.6M | $6.2M | $125,000 | $860,000 |
| Cash and investments | $3.5M | $1.5M | $4.9M | $4.9M | $8.8M |
| Total debt | $1.3M | $2.2M | $2.4M | $2.5M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 8, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 24, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 24, 2026 | Jul 22, 2026 |
All 242 FibroBiologics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.